OneTwenty.
The new kid on the block pump.
As a „fresh“ company we are combining state-of-the-art medical research, next gen technology and real life experience. All driven by our passion and ambition to bring innovation to market and people’s lives.
-
2018
Launch of ML research and precision nutrition program for PwT2D -
2019
ML models are being trained with real life data to predict BG levels and health impacting events -
2020
Data pool is massively expanded and additional models are being deployed for PwT1D -
2021
bioX® ML model suite is further developed to production level MLOps & work on the AID controller bioX® neoAP has begun -
2022
OneTwenty AG is born to accelerate growth and rapid development of proprietary technology -
2022
bioX® neoAP is externally benchmarked, delivers market-leading results and is being integrated by first innovative medtech companies